Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study
Casper W.F. van Eijck, Casper W F van Eijck, Disha Vadgama, van Eijck et autres
BACKGROUND: Beyond demographic and immune factors, metabolic considerations, particularly metformin's recognized impact in oncology, warrant exploration in treating pancreatic cancer. This study aimed to investigate the influence of metformin on patient survival and its potential correlation with distinct immune profiles in pancreatic …
nl (code pays fourni par la source)
35 citations
JNCI Journal of the National Cancer Institute